Head to Head Contrast: HeartBeam (NASDAQ:BEAT) and American Well (NYSE:AMWL)

HeartBeam (NASDAQ:BEAT) and American Well (NYSE:AMWL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Earnings & Valuation

This table compares HeartBeam and American Well”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01 million	($0.56)	-1.71
American Well	$249.32 million	0.51	-$95.70 million	($5.42)	-1.43

HeartBeam has higher earnings, but lower revenue than American Well. HeartBeam is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

7.8% of HeartBeam shares are owned by institutional investors. Comparatively, 56.1% of American Well shares are owned by institutional investors. 18.0% of HeartBeam shares are owned by company insiders. Comparatively, 12.8% of American Well shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares HeartBeam and American Well’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-1,034.04%	-434.40%
American Well	-37.02%	-32.11%	-24.12%

Analyst Ratings

This is a breakdown of recent ratings and target prices for HeartBeam and American Well, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1	2	4	1	2.63
American Well	1	4	1	0	2.00

HeartBeam presently has a consensus target price of $4.83, indicating a potential upside of 403.84%. American Well has a consensus target price of $7.30, indicating a potential downside of 5.89%. Given HeartBeam’s stronger consensus rating and higher possible upside, research analysts plainly believe HeartBeam is more favorable than American Well.

Risk and Volatility

HeartBeam has a beta of -0.86, meaning that its stock price is 186% less volatile than the S&P 500. Comparatively, American Well has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.

Summary

HeartBeam beats American Well on 8 of the 14 factors compared between the two stocks.

About HeartBeam

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

About American Well

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members. It provides Carepoint devices comprising carts, peripherals, tablets, and TVs, which serve as digital access points in clinical settings. In addition, the company offers Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, acute psychiatry, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.